aod9604 dosage PEPTIDE 2MG/5MG VIAL – UMBRELLA Labs AOD-9604 Dosage Guide: Protocols, Benefits,

consistent ~12-15% weight loss at 68 weeks Compound Tirzepatide (Zepbound) Class GIP/GLP-1 dual agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs

Demand CoAs

For more on this, see our guide to AOD 9604 in Miami: Fat Loss Peptide Facts, and how it is evaluated and treated at Perfect B in Doral

Beyond 500mcg, the risk-benefit ratio becomes less favorable

An interesting finding from the study was the rapid reduction in lameness observed in rabbits receiving the combination of AOD9604 and HA, with full recovery noted in approximately 11 days

Clinical trial results showed modest and variable weight loss outcomes